MDS has agreed to sell its Pharma Services division, with a CRO and private investors lined up to buy different sites, but approximately 275 employees will lose their jobs during the transition.
MDS believes its early stage business is likely to sell for less than previously expected because of the continued deterioration of market conditions and its declining customer base.
MDS Pharma Services has adopted SAS Drug Development to allow for closer collaboration with sponsors and provide a centralised, integrated system for data management and analysis.
The splitting up of MDS Pharma Services had little impact on the remaining business as there was limited integration anyway, according to a VP who detailed how the divestitures have allowed resources to be focused on core strengths.
MDS Pharma Services has become the first CRO in the UK and second in the US to gain certification from the Brazilian regulatory agency after a “major client” requested it sought accreditation.
Facing “unparalleled” challenges MDS is seeking a buyer for its Pharma Services division, and claims to have begun discussions with two interested parties, to allow it to focus on its Nordion business.
Canadian CRO MDS Pharma Services (MDS) is to sell its Phase II-IV trial business to US counterpart INC Research for $50m (€35m) and focus on providing discovery and early clinical development services.
MDS has announced it will help its customers confirm or repeat
analyses done at its contract research facilities in Quebec, after
the Food and Drug Administration (FDA) urged some drug makers to
retest products because of concerns...
Celgene has announced it has submitted a New Drug Application (NDA)
to the Food and Drug Administration (FDA) for its investigational
drug Revlimid, a first in a new class of novel immunomodulatory
drugs, or ImiDs.